Login to Your Account

NovaRx Moves into Phase III with Cancer Vaccine Lucanix

By Jennifer Boggs

Friday, August 22, 2008
Hoping to repeat its Phase II success, privately held NovaRx Corp. launched a pivotal study of therapeutic vaccine Lucanix (belagenpumatucel-L) in non-small-cell lung cancer (NSCLC) patients under a special protocol assessment approved early this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription